Selective Serotonin Reuptake Inhibitors (SSRIs) raise serotonin levels in the brain by binding to serotonin transporters and preventing its reuptake into presynaptic neurons. Serotonin is a key neurotransmitter involved in regulating mood, appetite, memory, reward pathways, and sleep cycles.

Fluoxetine Hydrochloride (Aladdin F131623) is an atypical SSRI with additional pharmacological actions — it shows moderate affinity for norepinephrine transporters, serotonin receptors, and sigma receptors, enabling it to also influence extracellular norepinephrine and dopamine concentrations.

Many antidepressants, including fluoxetine, possess analgesic or antinociceptive effects and demonstrate activity in experimental models of neuropathic pain and migraine. The pain-relieving properties of fluoxetine depend on modulation of both serotonergic and opioid systems.

Further research has examined fluoxetine’s effect on intracellular signaling kinases following mitogen stimulation. Through calcium mobilization, fluoxetine modulates PKC and PKA pathways, thereby influencing T-cell proliferation.

Some antidepressants also display anticancer potential—a notable benefit given the co-occurrence of mood disorders and certain cancers. Fluoxetine has been shown to reduce cell viability and trigger apoptosis in hepatocellular carcinoma cells by modulating MAPK signaling.

References:

Hashimoto K. Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):197-204.

Cervantes-Durán C, Rocha-González HI, Granados-Soto V. Neuroscience. 2013 Nov 12;252:396-409.

Edgar VA, Sterin-Borda L, Cremaschi GA, et al. Eur J Pharmacol. 1999 May 7;372(1):65-73.

Mun AR, Lee SJ, Kim GB, et al. Anticancer Res. 2013 Sep;33(9):3691-7.

Aladdin: https://www.aladdinsci.com/